These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31748376)

  • 1. Doublecortin-like Kinase 1 Regulates α-Synuclein Levels and Toxicity.
    Vázquez-Vélez GE; Gonzales KA; Revelli JP; Adamski CJ; Alavi Naini F; Bajić A; Craigen E; Richman R; Heman-Ackah SM; Wood MJA; Rousseaux MWC; Zoghbi HY
    J Neurosci; 2020 Jan; 40(2):459-477. PubMed ID: 31748376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.
    Bergeron M; Motter R; Tanaka P; Fauss D; Babcock M; Chiou SS; Nelson S; San Pablo F; Anderson JP
    Neuroscience; 2014 Jan; 256():72-82. PubMed ID: 24128992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
    Elfarrash S; Jensen NM; Ferreira N; Schmidt SI; Gregersen E; Vestergaard MV; Nabavi S; Meyer M; Jensen PH
    PLoS One; 2021; 16(10):e0252635. PubMed ID: 34613964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Druggable Genome Screen Identifies Modifiers of α-Synuclein Levels via a Tiered Cross-Species Validation Approach.
    Rousseaux MWC; Vázquez-Vélez GE; Al-Ramahi I; Jeong HH; Bajić A; Revelli JP; Ye H; Phan ET; Deger JM; Perez AM; Kim JY; Lavery LA; Xu Q; Li MZ; Kang H; Kim JJ; Shulman JM; Westbrook TF; Elledge SJ; Liu Z; Botas J; Zoghbi HY
    J Neurosci; 2018 Oct; 38(43):9286-9301. PubMed ID: 30249792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.
    Hong CT; Chen KY; Wang W; Chiu JY; Wu D; Chao TY; Hu CJ; Chau KD; Bamodu OA
    Cells; 2020 Mar; 9(3):. PubMed ID: 32192190
    [No Abstract]   [Full Text] [Related]  

  • 7. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
    Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD
    Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DCLK1 phosphorylates the microtubule-associated protein MAP7D1 to promote axon elongation in cortical neurons.
    Koizumi H; Fujioka H; Togashi K; Thompson J; Yates JR; Gleeson JG; Emoto K
    Dev Neurobiol; 2017 Apr; 77(4):493-510. PubMed ID: 27503845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
    Braithwaite SP; Stock JB; Mouradian MM
    Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy.
    Parmasad JA; Ricke KM; Nguyen B; Stykel MG; Buchner-Duby B; Bruce A; Geertsma HM; Lian E; Lengacher NA; Callaghan SM; Joselin A; Tomlinson JJ; Schlossmacher MG; Stanford WL; Ma J; Brundin P; Ryan SD; Rousseaux MWC
    Cell Death Dis; 2024 Apr; 15(4):246. PubMed ID: 38575601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polo-like kinase 2 modulates α-synuclein protein levels by regulating its mRNA production.
    Kofoed RH; Zheng J; Ferreira N; Lykke-Andersen S; Salvi M; Betzer C; Reimer L; Jensen TH; Fog K; Jensen PH
    Neurobiol Dis; 2017 Oct; 106():49-62. PubMed ID: 28648742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GV-971 attenuates α-Synuclein aggregation and related pathology.
    Yu Z; Yang Y; Chan RB; Shi M; Stewart T; Huang Y; Liu Z; Lan G; Sheng L; Tian C; Yang D; Zhang J
    CNS Neurosci Ther; 2024 Feb; 30(2):e14393. PubMed ID: 37563872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study.
    Dumitriu A; Pacheco CD; Wilk JB; Strathearn KE; Latourelle JC; Goldwurm S; Pezzoli G; Rochet JC; Lindquist S; Myers RH
    Hum Mol Genet; 2011 Apr; 20(8):1478-87. PubMed ID: 21258085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical β-catenin-dependent mechanism.
    Ali N; Nguyen CB; Chandrakesan P; Wolf RF; Qu D; May R; Goretsky T; Fazili J; Barrett TA; Li M; Huycke MM; Bronze MS; Houchen CW
    Sci Rep; 2020 Jun; 10(1):10578. PubMed ID: 32601309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
    Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
    Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization.
    Samuel F; Flavin WP; Iqbal S; Pacelli C; Sri Renganathan SD; Trudeau LE; Campbell EM; Fraser PE; Tandon A
    J Biol Chem; 2016 Feb; 291(9):4374-85. PubMed ID: 26719332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease risk genes act in glia to control neuronal α-synuclein toxicity.
    Olsen AL; Feany MB
    Neurobiol Dis; 2021 Nov; 159():105482. PubMed ID: 34390834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.
    Henderson MX; Chung CH; Riddle DM; Zhang B; Gathagan RJ; Seeholzer SH; Trojanowski JQ; Lee VMY
    J Neurosci; 2017 Jun; 37(24):5870-5884. PubMed ID: 28522732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
    Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
    Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.